000023125 000__ 01573cam\a22003855i\4500
000023125 001__ 23125
000023125 003__ SzGeWIPO
000023125 005__ 20240708161921.0
000023125 008__ 990623s1999\\\\enk\\\\\r\\\\u000\0\eng\d
000023125 035__ $$a(wipo)(CD )99-1159
000023125 035__ $$a(OCoLC)1159936840
000023125 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000023125 043__ $$aa-ja---
000023125 084__ $$a72$$qGB
000023125 1001_ $$aTessensohn, John A.,$$eauthor.
000023125 24510 $$aPharma companies lose more ground /$$cJohn A. Tessensohn.
000023125 264_1 $$aLondon [England] :$$bEuromoney Institutional Investor PLC,$$c1999.
000023125 300__ $$a1 volume ([3] pages) ;$$c[28] cm.
000023125 336__ $$atext$$btxt$$2rdacontent
000023125 337__ $$aunmediated$$bn$$2rdamedia
000023125 338__ $$avolume$$bnc$$2rdacarrier
000023125 4901_ $$aManaging Intellectual Property ;$$v1999 No 90 pages 14-17
000023125 500__ $$aJapan's Supreme Court has given to go-ahead to generics to use patented inventions for testing. How will pharmaceutical companies cope with that? Where does it leave Japan's TRIPs obligations?
000023125 650_0 $$aPatents$$zJapan.
000023125 650_0 $$aIntellectual property$$zJapan.
000023125 650_4 $$aPATENTS : PATENTABILITY : PHARMACEUTICAL PRODUCTS : JAPAN
000023125 650_4 $$aEXPERIMENTAL USE : SCOPE OF IMMUNITY : JAPAN
000023125 650_4 $$aDATA PROTECTION LAW : TRIPS : JAPAN
000023125 651_0 $$aJapan$$xCommerce$$xLaw and legislation.
000023125 7001_ $$aYamamoto, Shusak.
000023125 830_0 $$aManaging Intellectual Property ;$$v1999 No 90 pages 14-17.
000023125 903__ $$v1$$aMANAGING INTELLECTUAL PROPERTY
000023125 904__ $$aJournal article
000023125 942__ $$cART$$2ddc
000023125 952__ $$w2006-11-03$$p1999-1159$$r0.00$$u36295$$bMAIN$$10$$kGB 72$$v1999-06-23$$zMISSING$$70
000023125 980__ $$aBIB
000023125 999__ $$c25249$$d25249